Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by husk16on Nov 29, 2013 3:06pm

328 Views

Post# 21954504

RE:Q&A with Resverlogix - Very Interesting Answer Set

Thanks SanFran for posting your Q&A.  Does seem to be a lot of "We have no comment at this time"  So either #1 There is something going on and they are not allowed to comment. or #2 IR is just not allowed to say anything right now. Things are pretty dead here right now, but will pick up very, very quickly on any announcements. Hoping patience pays off.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale